S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.62 (-1.84%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.62 (-1.84%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.62 (-1.84%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.62 (-1.84%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
Positive News SentimentPositive News
NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Competitors

$11.58
+0.21 (+1.85%)
(As of 04:00 PM ET)
Compare
Today's Range
$11.23
▼
$11.78
50-Day Range
$11.29
▼
$13.98
52-Week Range
$4.82
▼
$14.92
Volume
289,373 shs
Average Volume
164,551 shs
Market Capitalization
$569.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

ALPN vs. ELVN, CNTA, PHAT, TYRA, BCYC, RAPT, GNLX, DYN, CALT, and KURA

Should you be buying Alpine Immune Sciences stock or one of its competitors? The main competitors of Alpine Immune Sciences include Enliven Therapeutics (ELVN), Centessa Pharmaceuticals (CNTA), Phathom Pharmaceuticals (PHAT), Tyra Biosciences (TYRA), Bicycle Therapeutics (BCYC), RAPT Therapeutics (RAPT), Genelux (GNLX), Dyne Therapeutics (DYN), Calliditas Therapeutics AB (publ) (CALT), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical preparations" industry.

Alpine Immune Sciences vs.

Alpine Immune Sciences (NASDAQ:ALPN) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

In the previous week, Enliven Therapeutics had 8 more articles in the media than Alpine Immune Sciences. MarketBeat recorded 9 mentions for Enliven Therapeutics and 1 mentions for Alpine Immune Sciences. Alpine Immune Sciences' average media sentiment score of 1.89 beat Enliven Therapeutics' score of 0.20 indicating that Alpine Immune Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Alpine Immune Sciences Very Positive
Enliven Therapeutics Neutral

Enliven Therapeutics has a net margin of 0.00% compared to Alpine Immune Sciences' net margin of -201.07%. Enliven Therapeutics' return on equity of -2.16% beat Alpine Immune Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Alpine Immune Sciences-201.07% -33.44% -21.43%
Enliven Therapeutics N/A -2.16%-2.08%

Alpine Immune Sciences presently has a consensus target price of $18.00, suggesting a potential upside of 55.44%. Enliven Therapeutics has a consensus target price of $27.00, suggesting a potential upside of 92.31%. Given Enliven Therapeutics' higher probable upside, analysts clearly believe Enliven Therapeutics is more favorable than Alpine Immune Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alpine Immune Sciences
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Enliven Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Alpine Immune Sciences has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

75.2% of Alpine Immune Sciences shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 42.3% of Alpine Immune Sciences shares are owned by company insiders. Comparatively, 45.8% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Alpine Immune Sciences received 362 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 64.60% of users gave Alpine Immune Sciences an outperform vote.

CompanyUnderperformOutperform
Alpine Immune SciencesOutperform Votes
365
64.60%
Underperform Votes
200
35.40%
Enliven TherapeuticsOutperform Votes
3
100.00%
Underperform Votes
No Votes

Enliven Therapeutics has lower revenue, but higher earnings than Alpine Immune Sciences. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpine Immune Sciences$30.06M18.95-$57.76M-$1.38-8.39
Enliven TherapeuticsN/AN/A$1.49M$2.994.70

Summary

Enliven Therapeutics beats Alpine Immune Sciences on 11 of the 16 factors compared between the two stocks.


Get Alpine Immune Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALPN vs. The Competition

Export to Excel
MetricAlpine Immune SciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$569.74M$6.05B$4.42B$6.20B
Dividend YieldN/A2.73%5.86%7.83%
P/E Ratio-8.395.06121.3111.96
Price / Sales18.95169.432,883.2766.39
Price / CashN/A19.0421.3922.77
Price / Book2.974.003.824.56
Net Income-$57.76M$202.28M$121.29M$181.66M
7 Day Performance-2.93%-1.86%-2.00%-1.97%
1 Month Performance-10.23%-11.57%-7.91%-9.14%
1 Year Performance65.43%3.09%7.16%1.95%

Alpine Immune Sciences Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELVN
Enliven Therapeutics
2.2451 of 5 stars		$14.27
+2.7%		$27.00
+89.2%		N/A$587.21MN/A4.7737Positive News
High Trading Volume
CNTA
Centessa Pharmaceuticals
2.0754 of 5 stars		$6.06
-1.3%		$8.50
+40.3%		+39.8%$590.24MN/A-3.3564News Coverage
PHAT
Phathom Pharmaceuticals
1.8698 of 5 stars		$10.26
-2.1%		$23.33
+127.4%		-8.4%$582.77MN/A-2.34112Positive News
TYRA
Tyra Biosciences
1.8629 of 5 stars		$13.46
-2.7%		$24.00
+78.3%		+48.9%$578.93MN/A-11.2238Positive News
BCYC
Bicycle Therapeutics
1.9883 of 5 stars		$19.90
-1.2%		$48.75
+145.0%		-14.3%$597.80M$14.46M-4.25236
RAPT
RAPT Therapeutics
2.4057 of 5 stars		$16.70
-2.7%		$37.20
+122.8%		-33.5%$573.81M$1.53M-6.21122Positive News
GNLX
Genelux
1.4766 of 5 stars		$22.44
-10.1%		$25.00
+11.4%		N/A$553.60M$11.24M0.0020Gap Down
High Trading Volume
DYN
Dyne Therapeutics
2.2859 of 5 stars		$9.01
+3.9%		$27.20
+201.9%		-37.5%$549.79MN/A-2.65134Gap Down
CALT
Calliditas Therapeutics AB (publ)
2.1197 of 5 stars		$18.40
-0.8%		$49.00
+166.3%		+12.4%$548.14M$79.63M-17.69169
KURA
Kura Oncology
1.8167 of 5 stars		$8.44
-1.5%		$25.93
+207.2%		-37.0%$626.59MN/A-4.12133

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:ALPN) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -